Abnormal intracellular level of bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients

F. Scamardella, Mariacaterina Maconi, L. Albertazzi, B. Gamberi, L. Gugliotta, M. Brini

Research output: Contribution to journalArticle

Abstract

B-cell chronic lymphocytic leukemia (B-CLL) is a lymphoproliferative disease caused by impaired apoptosis regulation that leads to an abnormal survival and an accumulation of B-lymphocytes. Anti-apoptotic Bcl-2 and pro-apoptotic Bax proteins are involved in the highly regulated mechanism of cell death. Bax and Bcl-2 intracellular levels were analyzed both in CD19+ and CD3+ cells from 28 B-CLL de novo patients and compared with cells from healthy donors. Our results were expressed as a ratio (Bax/Bcl-2) obtained by dividing Bax mean fluorescence intensity (MFI) and Bcl-2 MFI; obviously, a lower ratio is associated with an anti-apoptotic status, while a higher index correlates to apoptosis activation. In CD19+ B-CLL cells, the Bax/Bcl-2 ratio was lower than in the CD19+ normal counterpart (1.3 versus 3.51; P <.05), mainly due to a Bcl-2 over expression (17.65 versus 9.02; P <.001). In CD3+ cells from B-CLL patients, the Bax/Bcl-2 ratio was lower than in normal CD3+ cells (7.89 versus 8.96; P <.005), most importantly as a result of Bax suppression (77.22 versus 96.63; P <.001). These study data show an apoptosis inhibition not only in CD19+ cells, but also in CD3+ cells, suggesting a pivotal role of T-cells in B-CLL pathogenesis.

Original languageEnglish
Pages (from-to)187-192
Number of pages6
JournalLaboratory Hematology
Volume12
Issue number4
DOIs
Publication statusPublished - 2006

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Cells
Apoptosis
Fluorescence
bcl-2-Associated X Protein
T-cells
Lymphocytes
Cell death
Chemical activation
Apoptosis Regulatory Proteins
B-Lymphocytes
Cell Death
Tissue Donors
T-Lymphocytes
Survival

Keywords

  • Apoptosis
  • B-Cell chronic lymphocytic leukemia
  • Bax
  • Bcl-2
  • Intracellular level

ASJC Scopus subject areas

  • Hematology

Cite this

Abnormal intracellular level of bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients. / Scamardella, F.; Maconi, Mariacaterina; Albertazzi, L.; Gamberi, B.; Gugliotta, L.; Brini, M.

In: Laboratory Hematology, Vol. 12, No. 4, 2006, p. 187-192.

Research output: Contribution to journalArticle

Scamardella, F. ; Maconi, Mariacaterina ; Albertazzi, L. ; Gamberi, B. ; Gugliotta, L. ; Brini, M. / Abnormal intracellular level of bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients. In: Laboratory Hematology. 2006 ; Vol. 12, No. 4. pp. 187-192.
@article{537200f9199e4e589568b215eb7d354b,
title = "Abnormal intracellular level of bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients",
abstract = "B-cell chronic lymphocytic leukemia (B-CLL) is a lymphoproliferative disease caused by impaired apoptosis regulation that leads to an abnormal survival and an accumulation of B-lymphocytes. Anti-apoptotic Bcl-2 and pro-apoptotic Bax proteins are involved in the highly regulated mechanism of cell death. Bax and Bcl-2 intracellular levels were analyzed both in CD19+ and CD3+ cells from 28 B-CLL de novo patients and compared with cells from healthy donors. Our results were expressed as a ratio (Bax/Bcl-2) obtained by dividing Bax mean fluorescence intensity (MFI) and Bcl-2 MFI; obviously, a lower ratio is associated with an anti-apoptotic status, while a higher index correlates to apoptosis activation. In CD19+ B-CLL cells, the Bax/Bcl-2 ratio was lower than in the CD19+ normal counterpart (1.3 versus 3.51; P <.05), mainly due to a Bcl-2 over expression (17.65 versus 9.02; P <.001). In CD3+ cells from B-CLL patients, the Bax/Bcl-2 ratio was lower than in normal CD3+ cells (7.89 versus 8.96; P <.005), most importantly as a result of Bax suppression (77.22 versus 96.63; P <.001). These study data show an apoptosis inhibition not only in CD19+ cells, but also in CD3+ cells, suggesting a pivotal role of T-cells in B-CLL pathogenesis.",
keywords = "Apoptosis, B-Cell chronic lymphocytic leukemia, Bax, Bcl-2, Intracellular level",
author = "F. Scamardella and Mariacaterina Maconi and L. Albertazzi and B. Gamberi and L. Gugliotta and M. Brini",
year = "2006",
doi = "10.1532/LH96.06020",
language = "English",
volume = "12",
pages = "187--192",
journal = "Laboratory Hematology",
issn = "1080-2924",
publisher = "Carden Jennings Publishing Co. Ltd",
number = "4",

}

TY - JOUR

T1 - Abnormal intracellular level of bax in CD3+ cells from untreated B-cell chronic lymphocytic leukemia patients

AU - Scamardella, F.

AU - Maconi, Mariacaterina

AU - Albertazzi, L.

AU - Gamberi, B.

AU - Gugliotta, L.

AU - Brini, M.

PY - 2006

Y1 - 2006

N2 - B-cell chronic lymphocytic leukemia (B-CLL) is a lymphoproliferative disease caused by impaired apoptosis regulation that leads to an abnormal survival and an accumulation of B-lymphocytes. Anti-apoptotic Bcl-2 and pro-apoptotic Bax proteins are involved in the highly regulated mechanism of cell death. Bax and Bcl-2 intracellular levels were analyzed both in CD19+ and CD3+ cells from 28 B-CLL de novo patients and compared with cells from healthy donors. Our results were expressed as a ratio (Bax/Bcl-2) obtained by dividing Bax mean fluorescence intensity (MFI) and Bcl-2 MFI; obviously, a lower ratio is associated with an anti-apoptotic status, while a higher index correlates to apoptosis activation. In CD19+ B-CLL cells, the Bax/Bcl-2 ratio was lower than in the CD19+ normal counterpart (1.3 versus 3.51; P <.05), mainly due to a Bcl-2 over expression (17.65 versus 9.02; P <.001). In CD3+ cells from B-CLL patients, the Bax/Bcl-2 ratio was lower than in normal CD3+ cells (7.89 versus 8.96; P <.005), most importantly as a result of Bax suppression (77.22 versus 96.63; P <.001). These study data show an apoptosis inhibition not only in CD19+ cells, but also in CD3+ cells, suggesting a pivotal role of T-cells in B-CLL pathogenesis.

AB - B-cell chronic lymphocytic leukemia (B-CLL) is a lymphoproliferative disease caused by impaired apoptosis regulation that leads to an abnormal survival and an accumulation of B-lymphocytes. Anti-apoptotic Bcl-2 and pro-apoptotic Bax proteins are involved in the highly regulated mechanism of cell death. Bax and Bcl-2 intracellular levels were analyzed both in CD19+ and CD3+ cells from 28 B-CLL de novo patients and compared with cells from healthy donors. Our results were expressed as a ratio (Bax/Bcl-2) obtained by dividing Bax mean fluorescence intensity (MFI) and Bcl-2 MFI; obviously, a lower ratio is associated with an anti-apoptotic status, while a higher index correlates to apoptosis activation. In CD19+ B-CLL cells, the Bax/Bcl-2 ratio was lower than in the CD19+ normal counterpart (1.3 versus 3.51; P <.05), mainly due to a Bcl-2 over expression (17.65 versus 9.02; P <.001). In CD3+ cells from B-CLL patients, the Bax/Bcl-2 ratio was lower than in normal CD3+ cells (7.89 versus 8.96; P <.005), most importantly as a result of Bax suppression (77.22 versus 96.63; P <.001). These study data show an apoptosis inhibition not only in CD19+ cells, but also in CD3+ cells, suggesting a pivotal role of T-cells in B-CLL pathogenesis.

KW - Apoptosis

KW - B-Cell chronic lymphocytic leukemia

KW - Bax

KW - Bcl-2

KW - Intracellular level

UR - http://www.scopus.com/inward/record.url?scp=37849188279&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=37849188279&partnerID=8YFLogxK

U2 - 10.1532/LH96.06020

DO - 10.1532/LH96.06020

M3 - Article

C2 - 17118768

AN - SCOPUS:37849188279

VL - 12

SP - 187

EP - 192

JO - Laboratory Hematology

JF - Laboratory Hematology

SN - 1080-2924

IS - 4

ER -